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Gout is a common form of inflammatory arthritis for 
which highly effective treatments are available, yet 
the management of this disease is frequently subopti-
mal. Gout often presents as an acute ‘flare’ of painful 
inflammation that typically resolves within a week or 
two, but can be difficult to control in some instances, 
can negatively affect quality of life, can be costly to expe-
rience and treat, and can warrant hospital admission. If 
gout-associated hyperuricaemia is inadequately treated, 
gout flares often progress in frequency and severity, and 
a state of chronic, inflammatory arthritis can supervene, 
leading to continuous pain, decreased joint function, 
and permanent joint damage.
Guidelines for the management of gout are intended 
to help physicians select the most effective course of 
treatment and to educate patients in order to ensure 
adherence. In November 2016, the American College 
of Physicians (ACP) published a clinical practice guide-
line for the management of acute and recurrent gout1. 
Despite evaluating similar evidence, the ACP clinical 
practice guideline differs substantially from all other 
gout management guidelines issued by major interna-
tional rheumatology groups in the past 5 years, includ-
ing the 2012 American College of Rheumatology (ACR) 
guidelines2,3, 2014 3e (Evidence, Expertise, Exchange) 
Initiative recommendations4 and 2016 European League 
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Hyperuricaemia
Elevation of circulating level of 
urate.
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Abstract | In November 2016, the American College of Physicians (ACP) published a clinical 
practice guideline on the management of acute and recurrent gout. This guideline differs 
substantially from the latest guidelines generated by the American College of Rheumatology 
(ACR), European League Against Rheumatism (EULAR) and 3e (Evidence, Expertise, Exchange) 
Initiative, despite reviewing largely the same body of evidence. The Gout, Hyperuricemia and 
Crystal-Associated Disease Network (G-CAN) convened an expert panel to review the 
methodology and conclusions of these four sets of guidelines and examine possible reasons for 
discordance between them. The G-CAN position, presented here, is that the fundamental 
pathophysiological knowledge underlying gout care, and evidence from clinical experience and 
clinical trials, supports a treat-to-target approach for gout aimed at lowering serum urate levels 
to below the saturation threshold at which monosodium urate crystals form. This practice, which 
is truly evidence-based and promotes the steady reduction in tissue urate crystal deposits, is 
promoted by the ACR, EULAR and 3e Initiative recommendations. By contrast, the ACP does not 
provide a clear recommendation for urate-lowering therapy (ULT) for patients with frequent, 
recurrent flares or those with tophi, nor does it recommend monitoring serum urate levels of 
patients prescribed ULT. Results from emerging clinical trials that have gout symptoms as the 
primary end point are expected to resolve this debate for all clinicians in the near term future.
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Uricase
An enzyme that degrades uric 
acid to allantoin and water.
Tophi
Foreign body granuloma-like 
structures that form in reaction 
to large accumulations of 
monosodium urate crystals.
Pegloticase
A recombinant PEGylated 
uricase used as a therapy 
option in severe cases of gout.
Against Rheumatism evidence-based recommendations5 
(TABLE 1). This Consensus Statement summarizes the 
view of the Gout, Hyperuricemia and Crystal-Associated 
Disease Network (G-CAN) regarding these discordant 
gout management guidelines.
The authors of this consensus document are an inter-
national expert panel of rheumatologists with clinical and 
research interests in gout and hyperuricaemia. This paper 
presents the rationale for the G-CAN position on guide-
lines for the management of gout; provides the G-CAN 
interpretion of, and specific responses to, the ACP rec-
ommendations; and examines the basis for the discord-
ance between the ACP guidelines and those produced by 
the various rheumatology groups. This paper also dis-
cusses prospects for closing the gap between these 
recommendations by further clinical studies in the field.
Methods
The G-CAN panel, selected by the G-CAN Directorship 
(President (R.T.) and Vice President (H.K.C.)), consisted 
of a small cross-section of international gout experts 
from among active members of the organization (T.B., 
M.D., P.R., K.G.S. and L.K.S.) and G-CAN board mem-
bers (H.K.C, N.D. F.L., R.T. and A.K.S.). Each panel 
member independently assessed the core aspects of the 
ACP gout guideline and were asked to vote on whether 
to accept or reject each ACP guideline recommendation. 
Collective assessments of the ACP guideline were tabu-
lated and recorded by R.T. and H.K.C., and are presented 
in TABLE 1, which also compares the individual ACP 
gout recommendations to prior recommendations by 
rheumatology (ACR, EULAR and 3e Initiative) panels.
Rationale for the G‑CAN position
Unlike many other diseases, the particularly lucid 
understanding of the pathophysiology of gout provides 
a remarkably clear rationale for treatments that address 
the underlying cause of the disorder (FIG. 1). The cardinal 
pathophysiologic aspects of gout, which inform effective 
management (and thus underlie the G-CAN position), 
are outlined in this section.
Gout, a chronic disease with acute exacerbations, is 
driven by monosodium urate (MSU) crystal deposition 
caused by hyperuricaemia; without serum levels of uric 
acid above the saturation point (and the resulting MSU 
crystals), gout does not exist — as is the case in non- 
primate mammals, which have uricase and thus serum 
urate levels ~10 times lower than that of humans.
MSU crystals form in vitro at saturation concentra-
tions (>6.8 mg/dl (>405 μmol/l) at pH 7.0 and a tempera-
ture of 37 °C, and >6.0 mg/dl (>360 μmol/l) at pH 7.0 and 
a temperature of 35 °C)6,7. Pathology, imaging and inter-
vention studies have demonstrated that the clinical mani-
festations of gout occur because of the host inflammatory 
response to deposited MSU crystals8–13, exemplified by 
acute gout flares10. The acute flares characteristically 
present as an exquisitely painful inflammatory arthritis14, 
which leads to severe limitation of activity, poor quality 
of life and work disability15. These events are highly con-
sequential to the health-related quality of life of affected 
patients, and also have added socioeconomic effects16.
Tophi are a cardinal feature of gout12. The tophus 
can discharge and ulcerate, restrict joint movement, 
cause joint damage (including bone erosion) and have 
a severe impact on quality of life15,17,18. In the majority of 
patients, tophi are the consequence of years of untreated 
or undertreated hyperuricaemia19,20.
Urate-lowering drugs, including allopurinol, when 
successfully employed to reduce the serum urate level 
to below saturation concentrations, promote dissolu-
tion of MSU crystals in the joints (including on the sur-
face of articular cartilage, in other joint tissues, and in 
synovial fluid)21,22 (FIG. 1) and, therefore, removal of the 
root cause of disease. The velocity of crystal dissolution 
is dependent on the urate concentration23,24. Long-term 
studies have shown the clear clinical benefit of treating 
patients with urate-lowering therapy (ULT) to reach 
target serum urate levels, with complete suppression 
of flares, regression of tophi and improvement in qual-
ity of life over time21,25–30. Bone erosions due to topha-
ceous gout also have been shown to heal after expedited 
eradication of tissue MSU crystal deposits by use of 
pegloticase therapy31. The treat-to-target ULT approach 
involves gradually increasing the dose of ULT to 
achieve the target serum urate concentration, which 
needs to be monitored periodically. Anti-inflammatory 
prophylaxis of acute gout flares is commonly employed 
adjunctively in the early phase of treat-to-target ULT, as 
remodelling of tissue MSU crystal deposits by effective 
ULT can induce a temporary increase in the frequency 
of acute gout flares.
Assessment of the ACP recommendations
The G-CAN position on each of the four ACP recom-
mendations for the management of gout is summarized 
in TABLE 2. Although the G-CAN panel agreed with some 
of the recommendations in whole or in part, there are 
some fundamental issues the panel concluded to be flaws 
in the ACP clinical practice guideline, specifically con-
cerning the lack of clear advice about ULT for patients 
with recurrent flares, ULT for patients with tophi, and 
serum urate level monitoring for patients on ULT.
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ACP indications for ULT
The G-CAN panel unanimously rejected the ACP 
recommendation against initiating long-term ULT in 
most patients after a first gout attack or in patients with 
fewer than two acute gout flares annually. In particular, 
the G-CAN panel expressed concern about the lack of 
clarity of this recommendation, as it applies specifically 
to patients with a first gout flare or infrequent acute 
gout flares without consideration of other indications 
for ULT besides acute gout flares (such as the presence 
of a palpable tophus (or tophi) or chronic synovitis due 
to gout). The ACP clinical practice guideline does not 
provide a clear recommendation about management 
of patients with gout and one or more palpable tophi, 
in stark contrast to rheumatology guidelines that rec-
ommend palpable gouty tophi as a definite indication 
for ULT. The G-CAN panel also expressed concern 
that this ACP recommendation ignores aspects of 
recurrent acute gout flares other than flare frequency 
(such as severity, responsiveness to therapy, number of 
joints affected, functional impairment or the need for 
emergency medical care and/or hospital admission), 
and also ignores the presence of comorbidities (which 
narrows the options for treatment of acute gout flares) 
Table 1 | Summary of recent major gout guidelines methods and conclusions
Feature ACR (2012)2,3 3e Initiative (2014)4 EULAR (2016)5 ACP (2016)1
Background of 
authors
• Rheumatologists (23)
• Primary care physicians (3)
• Nephrologist (1)
• Patient advocate (1)
• Medical trainees (5)
Rheumatologists (474) • Rheumatologists (15)
• Radiologist (1)
• Primary care physicians (2)
• Research trainee (1)
• Patient advocates (2)
• Non-physician 
methodologists (3)
• Primary care physicians (3)
Other decision-making committee 
members:
• primary care physicians (9),
• rheumatologist (1),
• pulmonologist (1)
Authors’ location(s) International (USA, Europe, 
New Zealand)
Multinational (14 
countries)
Europe (12 European nations) USA
Methodology Followed the RAND/
UCLA method, involving 
systematic literature 
review, the use of a 
core expert panel to 
develop case scenarios, 
preparation of a scientific 
evidence report (published 
in part) and a task force 
panel vote on the case 
scenarios, with subsequent 
ACR peer-review prior to 
publication
Ten clinically relevant 
questions were selected 
via a modified Delphi 
voting process, followed 
by systematic literature 
reviews, evaluation and 
grading of evidence, 
international scientific 
committee agreement, 
and Delphi process 
to produce the final 
recommendations
Standardized operating 
procedure endorsed by 
EULAR for the elaboration, 
evaluation, dissemination 
and implementation of 
recommendations. This 
process included systematic 
literature review, evaluation 
and grading of evidence, 
panel agreement and 
peer-review
Evidence-based approach as 
advocated by the Institute of 
Medicine, and using GRADE 
guideline methods, which assessed 
benefits, risks and burden. The 
process included systematic 
evidence review, grading of 
evidence, committee agreement 
and peer-review. RCT and clinical 
outcomes were emphasized, rather 
than the outcome of lower serum 
urate (which was viewed as a 
surrogate outcome)
Management guidance provided
Acute gout (NSAIDs, 
corticosteroids, 
colchicine)
+ + + +
Use of low-dose 
colchicine for acute 
gout
+ + + +
Comorbidity 
screening
+ + + No clear advice
ULT indicated 
for patients with 
frequent flares
+ Not assessed + No clear advice
ULT indicated 
for patients with 
palpable tophi
+ + + No clear advice
Low starting dose 
of allopurinol, with 
dose escalation
+ + + No clear advice
Treat-to-target ULT + + + No clear advice
Monitoring of serum 
urate levels
+ + + No clear advice
Pegloticase + + + Not assessed
3e, Evidence, Expertise, Exchange; ACP, American College of Physicians; ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; 
GRADE, Grading of Recommendations Assessment, Development, and Evaluation; RAND/UCLA, Research and Development/University of California at Los 
Angeles; RCT, randomized controlled trial; ULT, urate-lowering therapy.
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Allopurinol hypersensitivity 
syndrome
A syndrome of severe 
hypersensitivity to allopurinol 
that is commonly associated 
with one or more of fever, rash, 
eosinophilia and multi-system 
organ damage and that has a 
high mortality rate.
and presence of marked hyperuricaemia unlikely to 
resolve adequately with conservative treatment. This 
assessment by the G-CAN panel is in line with most 
rheumatology society guidelines, which advocate long-
term ULT for specific patient scenarios2, including in 
early gout5.
ACP information for patients
The G-CAN expert panel unanimously agreed that 
patients should be given full information on their con-
dition, available treatment options and the expected 
benefits and possible adverse effects of individual 
treatments, as laid out in ACP recommendation 4. 
However, this principle applies to every medical 
encounter and is as relevant to treatments for acute 
attacks as it is for long-term ULT. The G-CAN expert 
panel unanimously agreed that recommendation 4 
lacks any clear advice concerning ULT and anti- 
inflammatory flare prophylaxis, and that this rec-
ommendation lacks sufficient specificity to provide 
practical guidance to clinicians.
Other issues
Several other important clinical practice points were 
not addressed by the ACP clinical practice guideline, 
including the time to commencement and duration of 
ULT. Notably, the ACP clinical practice guideline does 
not advocate either regular serum urate measurements 
or dose titration of ULT to reduce the serum urate level 
to a specific target; by contrast, the ACR, EULAR and 3e 
Initiative guidelines all recommend the treat-to-target 
approach for ULT. Moreover, the ACP guideline empha-
sized the risks of ULT, yet core elements of allopurinol 
risk management aimed at limiting allopurinol hyper-
sensitivity syndrome (AHS) were omitted. Specifically, 
the ACP guideline did not adequately address either the 
strategy to avoid AHS by starting with a low initial dose 
of allopurinol before titrating upwards32 or the valuable 
role of screening for HLA‑B*5801 to identify patients 
at markedly elevated risk of AHS within multiple well- 
defined ethnic and racial groups (such as Han Chinese, 
Korean, Thai, East Indian and African-American 
populations)33,34. G-CAN also supports screening for 
Urate crystals
Synovium
Cartilage
Bone
Articular urate crystal
deposition in gout
Dissolution of
urate crystals
Tophus
Nature Reviews | Rheumatology
Rheumatology society-recommended treatment
objectives and approach
• Ultimate resolution of gouty arthritis symptoms
• Intermittent anti-inﬂammatory treatment for acute
 ﬂare
• Limited-term anti-inﬂammatory ﬂare suppression
• Long-term ‘treat to target’ ULT to lower serum urate
 level and steadily reduce articular and periarticular
 urate crystal deposits
• Prevention of joint damage
ACP-recommended treatment objectives and
approach
• Intermittent anti-inﬂammatory treatment
for acute ﬂare
• ‘Treat to avoid symptoms’
• No clear recommendations for ULT, serum urate
 target, serum urate monitoring or ULT duration
• No clear objective to reduce articular and
 periarticular urate crystal deposits or prevent
 joint damage
Chronic synovitis
and joint damage
Figure 1 | Schematic comparison of expected clinical-pathologic outcomes of gout from guidelines for the 
management of gout. The schematic illustrates the main emphases of major guidelines for gout produced by 
rheumatology societies (left side of figure), compared with the American College of Physicians (ACP) guideline (right side), 
arising from differing perceptions of gout. Guidelines developed by expert rheumatology societies take into account gout 
pathophysiology and clinical course, generally seeing gout as a chronic condition with acute inflammatory flares and the 
frequent tendency, due largely to under-treatment of hyperuricaemia (rather than ‘treat to target’ urate-lowering therapy 
(ULT)), to progress to the development of palpable tophi, chronic synovitis and joint damage (including bone erosion). By 
contrast, the ACP guidance to ‘treat to avoid symptoms’ reflects a perception of gout as primarily an intermittent disorder 
of acute inflammation.
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comorbid conditions that are frequently associated with 
gout, such as chronic kidney disease and cardiovascular 
disease, as advocated by the 2012 ACR gout guidelines2, 
but not mentioned in the ACP guidelines.
The G-CAN panel is very concerned that the ACP 
clinical practice guideline, using methodology that 
attempts to balance the benefits of therapy with risks 
and burden35, does not provide a clear recommendation 
for ULT in patients with recurrent attacks. Most patients 
achieve effective urate-lowering with a single agent when 
individually dose-titrated36. Moreover, urate-lowering 
drugs are generally safer and better tolerated than fre-
quently used anti-inflammatory drugs such as colchicine, 
NSAIDs or high-dose corticosteroids, particularly so in 
patients with comorbidities commonly associated with 
gout, including chronic kidney disease, hypertension, 
type 2 diabetes mellitus and ischemic heart disease37–39.
Clearly, including guidance on these aspects of prac-
tice within the ACP clinical practice guideline would 
have had a major effect on the safety and effectiveness 
of management of gout in primary care.
Reasons for discordance
The discordance between the ACP guideline and 
the various rheumatology panel guidelines (including the 
G-CAN assessment) cannot simply be ascribed to differ-
ences in general methodologic approaches taken by these 
groups40,41. Many discordances extend from differences in 
the interpretation of the literature with respect to ULT.
Clinical benefits of successful ULT
The G-CAN position is that the medical literature over-
whelmingly supports the concept that clinical benefits are 
observed in patients with gout who achieve long-term 
serum urate lowering to sub-saturation concentrations. 
Specifically, all open-label extension studies of rand-
omized controlled trials (RCTs) of orally administered 
ULT have shown improvement in flares, tophus size 
and other clinically important outcomes over periods of 
>1 year of therapy27–30. Furthermore, RCTs of pegloticase, 
a parenteral agent which promotes profound serum urate 
lowering and rapid clearance of MSU crystals, clearly 
demonstrate that intensive lowering of serum urate lev-
els leads to reductions in flares and tophus size and to 
improvements in health-related quality of life and activity 
limitation, even over a 6-month treatment period42,43. In 
addition, those patients with a durable response to peglot-
icase (with serum urate level <6 mg/dl) have an enduring 
improvement in all relevant clinical outcomes29,30. The 
ACP Clinical Guidelines Committee decided not to con-
sider the pegloticase clinical trial data because pegloticase 
was considered an agent unlikely to be prescribed by pri-
mary care physicians44. Nevertheless, the high level of evi-
dence showing a clear clinical benefit of this highly potent 
urate-lowering agent should help confirm the therapeu-
tic principle of the treat-to-target ULT approach, already 
universally adopted by rheumatology guidelines.
Interpreting limits of past ULT trials
A guiding doctrine of the ACP guideline was that ret-
rospective studies and even RCTs that used the decline 
in serum urate level to a pre-stipulated target as an indi-
rect, surrogate outcome, rather than demonstrating the 
improvement in a clinical outcome such as reduction in 
frequency of acute gout flares during the randomized 
phase of an RCT, were insufficient data for the stand-
ard of evidence-based guidelines defined by the Institute 
of Medicine (since renamed the National Academy of 
Medicine)40. G-CAN, like the ACP and rheumatology 
society panels, recognized that no long-term (that is, 
more than 12 months’ duration) RCTs have specifically 
examined the treat-to-target approach to gout manage-
ment. Moreover, the G-CAN expert panel, and a largely 
separate panel of rheumatologists45, agree with the ACP 
panel that evidence is still lacking for reduction in fre-
quency of acute gout flares by oral ULT measures dur-
ing the randomized, controlled phase of clinical trials. 
However, G-CAN strongly supports the treat-to-target 
Table 2 | Summary of the G-CAN position on the ACP recommendations for gout management1
ACP recommendation Strength and basis of recommendation G-CAN assessment
1. ACP recommends that clinicians choose 
corticosteroids, NSAIDs or colchicine to treat patients 
with acute gout
Strong recommendation, high-quality 
evidence
The G-CAN gout expert panel unanimously 
supported this recommendation
2. ACP recommends that clinicians use low-dose 
colchicine when using colchicine to treat acute gout
Strong recommendation, moderate-quality 
evidence
The G-CAN gout expert panel unanimously 
supported this recommendation
3. ACP recommends against initiating long-term ULT 
in most patients after a first gout attack or in patients 
with infrequent attacks (that is, <2 acute gout flares 
per year)
Strong recommendation, moderate-quality 
evidence
The G-CAN gout expert panel unanimously 
rejected this recommendation
4. ACP recommends that clinicians discuss benefits, 
harms, costs and individual preferences with 
patients before initiating ULT, including concomitant 
prophylaxis, in patients with recurrent gout attacks
Strong recommendation, moderate-quality 
evidence
The G-CAN expert panel unanimously agreed 
that patients should be given full information 
as laid out in this recommendation, but 
expressed concern that this recommendation 
lacks any clear advice concerning ULT and 
anti-inflammatory flare prophylaxis, and lacks 
sufficient specificity to provide practical 
guidance to clinicians
The ACP clinical practice guideline made four recommendations for the management of acute and recurrent gout, and were aimed at ‘all clinicians’ (REF. 1).  
ACP, American College of Physicians; G-CAN, Gout, Hyperuricemia and Crystal-Associated Disease Network; ULT, urate-lowering therapy.
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ULT strategy, as the various rheumatology groups 
have consistently done, on the basis of the breadth 
of available evidence, including long-term, open- 
label extensions of oral ULT RCTs, prospective obser-
vational studies, and the trials of intensive ULT with 
pegloticase45. By comparison, the hierarchical approach 
to evidence used by the ACP panel placed unbending 
emphasis on the randomized controlled phases of clin-
ical trials. The G-CAN panel’s assessment is that the 
ACP approach was probably too rigid for the evidence 
in gout, where the collective data provide very high 
confidence for disease- modifying effects of effective 
serum urate- lowering, consistent with the remarkably 
well-understood pathophysiology of gout (FIG. 1).
Different approaches, different conclusions
The ACP reached evidence-based health care decisions 
using the Grading of Recommendations Assessment, 
Development, and Evaluation (GRADE) approach, 
which assessed benefits, risks and burden and which 
places a much higher emphasis on clinical outcomes 
that patients are directly aware of (for example, symptom 
severity or quality of life) than on surrogate outcomes 
(such as serum uric acid level in gout). By contrast, the 
rheumatology panels perceived the uric acid burden 
— reflected not only by hyperuricaemia, but also by 
chronic, progressive tissue inflammation and joint dam-
age — as a crucial aspect of the disease burden in gout. 
As such, differences between the final conclusions of the 
ACP and the rheumatology panels (TABLE 1) reflect major 
differences in the perceived importance of periodic 
symptoms and of the chronic disease burden in gout.
Merits of evidence-based practice approach
The G-CAN position is that the multiple scenarios and 
clinical phenotypes of gout, an understanding of rational 
treatment directed to gout pathophysiology, and the 
current state of evidence in gout, make a three-pillared 
evidence-based practice (EBP) approach more appro-
priate41. The principles of this approach are that treat-
ment is based on the best available research evidence, the 
expertise of the clinician as applied to the diagnosis and 
overall health status of each patient coupled with assess-
ment of the risk–benefit balance of potential therapies, 
and the preferences and values of the patient. This EBP 
approach was taken by the ACR, EULAR and 3e Initiative 
in construction of their respective gout management 
recommendations, but not by the ACP (TABLE 1). As a 
consequence, several fundamental aspects of EBP gout 
management covered in the major rheumatology guide-
lines are not clearly addressed in the ACP recommenda-
tions, namely the use of ULT in patients with recurrent 
gout attacks, ULT in patients with gout and one or more 
palpable tophi, and monitoring patients taking ULT.
The decision-making in the ACP clinical practice 
guideline is difficult to comprehend in part because their 
systematic review acknowledges that moderate-to-high 
quality evidence shows that ULT reduces the risk of 
acute gout attacks after 1 year of follow-up1. This find-
ing is based on data from studies that employed a fixed 
dose of ULT (as opposed to the recommended upwards 
titration of ULT dose), which would have underestimated 
clinical benefit46–48. Furthermore, when using oral ULT 
at the low doses frequently prescribed in clinical prac-
tice, MSU crystal dissolution can be slow, particularly in 
patients with prolonged disease duration or if the serum 
urate level is not intensively lowered22. For this reason, the 
clinical benefits of oral ULT for flares, chronic synovitis 
or tophi often take many months or several years after 
treatment is initiated. Substantial benefits with respect 
to clinical end points for gout have been reported in 
publications of the longer-duration open-label studies of 
oral ULT, beyond the randomized phase of clinical tri-
als27,28,49–51. In the end, these data did not sway the ACP 
when considering the value of long-term oral ULT.
Consequences of guideline discordance
The ACP clinical practice guideline1, which is stated to 
be intended for ‘all clinicians’, instead reflects an appar-
ent chasm within the medical community (FIG. 1) regard-
ing the perception of patients with gout — a chasm that 
is multifactorial and longstanding. Clinicians in primary 
care and acute care settings might treat patients for acute 
‘attack’ symptoms, which could reinforce a view of gout 
as an intermittent and, in many cases, self-inflicted dis-
ease. In many cases, clinicians can deem gout a lesser 
priority than comorbid issues. Gout-specific patient 
education and gout outcomes correspondingly suffer. 
By contrast, rheumatologists generally see gout as a 
chronic, very often progressive, condition that has acute 
flares but a tendency to progress. With gout increasing 
in prevalence, and with so many patients being older 
and affected by multiple comorbidities, gout is becoming 
more challenging to manage, as indicated (in part) by 
a marked increase in severe acute gout flares requiring 
hospitalization52,53.
The G-CAN position is that the ACP’s stance on ULT, 
essentially that ULT can be prescribed without urate 
monitoring or optimization of ULT dose to achieve 
urate concentrations below the saturation threshold of 
soluble urate1, is particularly troubling as it could help 
perpetuate the common practice pattern of underdosing 
of ULT54. Prescribing a drug without consideration of an 
individual patient’s response to the specific intent of the 
medication (in this case, ULT without monitoring 
urate levels) lacks logic or clinical sense. This practice 
would be analogous to prescribing anti-hypertensive 
medication without measuring blood pressure or hypo-
glycaemic therapy without measuring HbA1c (glycated 
haemoglobin) levels. Moreover, adherence is a major 
issue for patients who have commenced ULT55, and 
serum urate testing enables direct, objective assessment 
of adherence to ULT. The results of such testing often 
prompt the clinician to initiate further discussions with 
the patient about gout management, including ULT, as 
advocated in the ACP clinical practice guideline36.
The ACP clinical practice guideline focus on high-
value care is laudable. The authors noted that “an esti-
mated $1 billion is spent annually on ambulatory care 
for gout, largely on treatments and prescription med-
ications”1. At present, however, most of the costs of 
treating gout relate to management of acute flares and 
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poorly controlled disease56–58 and most patients with gout 
do not receive ULT or regular serum urate testing54,59. 
Rheumatology opinion, shared by the G-CAN panel, 
is that the benefits of this test in guiding individualized 
patient care far outweigh its small costs (and indeed far 
outweigh the direct and indirect costs of poorly con-
trolled gout)2. Similarly, allopurinol, the most widely used 
ULT drug, has been available for more than 60 years, 
and the cost of generic allopurinol is low. A 2014 cost- 
effectiveness analysis incorporating all available evidence 
found that allopurinol therapy is cost-saving, particularly 
when using an up-titration approach to dosing60.
The G-CAN position is that widespread adoption of the 
ACP clinical practice guideline, with its focus on episodic 
acute gout therapy and lack of clear recommendations 
regarding indications for ULT or serum urate monitoring, 
has the potential to perpetuate clinical (therapeutic) iner-
tia61, leading to a greater burden of poorly managed gout 
and rising costs to affected patients and society.
G-CAN also is highly concerned that failure to 
provide clear indications for ULT or advocate serum 
urate monitoring ignores available data for the allure of 
so-called ‘absence of evidence’, which we know not to be 
‘evidence of absence’ to support long-term ULT in gout.
Another apprehension of the G-CAN panel is that the 
ACP clinical practice guideline could promote excessive 
use of NSAIDs, colchicine and prednisone for long-term 
‘symptom suppression’ in gout, due to lack of attention 
to core disease pathophysiology.
Addressing the evidence gaps
The results of completed and new RCTs of urate- 
lowering agents and strategies that will be published 
over the next few years are eagerly awaited. One exam-
ple is a 2-year double-blind, placebo-controlled trial of 
titrated treat-to-target ULT in patients with early gout 
that includes radiographic analyses of bone erosion, 
MRI imaging of bone erosion, bone marrow oedema 
and synovitis, and flares62. Another example is a con-
trolled trial, conducted in Nottingham, UK, comparing 
primary care management of gout with nurse-led titra-
tion of ULT according to the treat-to-target ULT strategy 
recommended by rheumatology society guidelines63.
Furthermore, the ACP and the G-CAN panel are in 
agreement that well-designed, prospective, controlled 
clinical trials are needed to clarify several issues around 
ULT. Questions to be resolved concern determining 
the effect of ULT on adverse health outcomes beyond 
acute gout, the duration of ULT, and the optimum serum 
urate target for reduction of symptoms, comorbidities 
and minimal harms (in addition to confirming the clin-
ical efficacy and safety of the treat-to-target approach). 
Studies are also needed to establish the risk of recurrent 
acute gout attacks, symptomatic chronic gout, comor-
bidities and disability following a first attack of gout, 
in order to inform clinicians and patients considering 
the potential costs, benefits and harms of commencing 
ULT or delaying treatment until further attacks have 
occurred.
Conclusions
Guidelines for the management of gout developed by the 
ACP primary care in comparison to the rheumatology 
society gout guidelines groups (namely ACR, EULAR 
and 3e Initiative) are discordant, despite assessment of 
largely the same evidence, with the exception of trials 
of pegloticase. Other published assessments of the ACP 
guideline for gout64,65 and of the value of treat-to- target 
ULT56,66 buttress the opinions of the G-CAN panel pre-
sented in this paper. However, controversy persists, since 
support has also been voiced for the ACP guidelines67. 
The G-CAN panel believes that emerging and future 
studies will enable alignment and consensus in guide-
lines for primary care physicians, rheumatologists and 
other specialists involved in management of patients 
with gout.
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